The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design
There is broad interest in improved methods to generate robust evidence regarding best practice, especially in settings where patient conditions are heterogenous and require multiple concomitant therapies. Here, we present the rationale and design of a large, international trial that combines featur...
Gespeichert in:
Veröffentlicht in: | Annals of the American Thoracic Society 2020-07, Vol.17 (7), p.879-891 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 891 |
---|---|
container_issue | 7 |
container_start_page | 879 |
container_title | Annals of the American Thoracic Society |
container_volume | 17 |
creator | Angus, Derek C Berry, Scott Lewis, Roger J Al-Beidh, Farah Arabi, Yaseen van Bentum-Puijk, Wilma Bhimani, Zahra Bonten, Marc Broglio, Kristine Brunkhorst, Frank Cheng, Allen C Chiche, Jean-Daniel De Jong, Menno Detry, Michelle Goossens, Herman Gordon, Anthony Green, Cameron Higgins, Alisa M Hullegie, Sebastiaan J Kruger, Peter Lamontagne, Francois Litton, Edward Marshall, John McGlothlin, Anna McGuinness, Shay Mouncey, Paul Murthy, Srinivas Nichol, Alistair O'Neill, Genevieve K Parke, Rachael Parker, Jane Rohde, Gernot Rowan, Kathryn Turner, Anne Young, Paul Derde, Lennie McArthur, Colin Webb, Steven A |
description | There is broad interest in improved methods to generate robust evidence regarding best practice, especially in settings where patient conditions are heterogenous and require multiple concomitant therapies. Here, we present the rationale and design of a large, international trial that combines features of adaptive platform trials with pragmatic point-of-care trials to determine best treatment strategies for patients admitted to an intensive care unit with severe community-acquired pneumonia. The trial uses a novel design, entitled "a randomized embedded multifactorial adaptive platform." The design has five key features:
) randomization, allowing robust causal inference;
) embedding of study procedures into routine care processes, facilitating enrollment, trial efficiency, and generalizability;
) a multifactorial statistical model comparing multiple interventions across multiple patient subgroups;
) response-adaptive randomization with preferential assignment to those interventions that appear most favorable; and
) a platform structured to permit continuous, potentially perpetual enrollment beyond the evaluation of the initial treatments. The trial randomizes patients to multiple interventions within four treatment domains: antibiotics, antiviral therapy for influenza, host immunomodulation with extended macrolide therapy, and alternative corticosteroid regimens, representing 240 treatment regimens. The trial generates estimates of superiority, inferiority, and equivalence between regimens on the primary outcome of 90-day mortality, stratified by presence or absence of concomitant shock and proven or suspected influenza infection. The trial will also compare ventilatory and oxygenation strategies, and has capacity to address additional questions rapidly during pandemic respiratory infections. As of January 2020, REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) was approved and enrolling patients in 52 intensive care units in 13 countries on 3 continents. In February, it transitioned into pandemic mode with several design adaptations for coronavirus disease 2019. Lessons learned from the design and conduct of this trial should aid in dissemination of similar platform initiatives in other disease areas.Clinical trial registered with www.clinicaltrials.gov (NCT02735707). |
doi_str_mv | 10.1513/annalsats.202003-192sd |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7328186</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2419750237</sourcerecordid><originalsourceid>FETCH-LOGICAL-c561t-e88cd873c5ba4c55b98dc823bfe3b0fda80357410245a90b793e13117cb1334b3</originalsourceid><addsrcrecordid>eNpdkUtP3DAUhaOqqCDgLyBL3dBFpn7EsbOpFA3ThwTqaGa6thzbAaPEHmwHabrjn2MYigpe2FfyOefeq68ozhCcIYrIV-mcHKJMcYYhhpCUqMFRfyiOMMG0rGuMPj7XTVk3hBwWpzHewnw4RZw1n4pDgnHNGENHxcPmxoDV4qpdlvN2Cc5X0mk_2r9Gg8XYGa1zcTUNyfZSJR-sHECr5TbZewOWg0y9DyPIF5j7cZycTbtSqrvJhuxbOjON3ln5BazTpHczsJLJ-jy7AbkNuDDRXruT4qDP25jTl_e4-PN9sZn_LC9___g1by9LRWuUSsO50pwRRTtZKUq7hmvFMel6QzrYa8khoaxCEFdUNrBjDTGIIMRUhwipOnJcfNvnbqduNFoZl4IcxDbYUYad8NKKtz_O3ohrfy8YwRzxOgecvwQEfzeZmMRoozLDIJ3xUxSYcA4hghXM0s_vpLd-Ck_QBK5QwyjEhGVVvVep4GMMpn8dBkHxBFq0z6DbzVrsQYsMen2RjWf_r_Jq-4eVPAJ6Raej</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2419750237</pqid></control><display><type>article</type><title>The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design</title><source>MEDLINE</source><source>American Thoracic Society (ATS) Journals Online</source><source>Alma/SFX Local Collection</source><creator>Angus, Derek C ; Berry, Scott ; Lewis, Roger J ; Al-Beidh, Farah ; Arabi, Yaseen ; van Bentum-Puijk, Wilma ; Bhimani, Zahra ; Bonten, Marc ; Broglio, Kristine ; Brunkhorst, Frank ; Cheng, Allen C ; Chiche, Jean-Daniel ; De Jong, Menno ; Detry, Michelle ; Goossens, Herman ; Gordon, Anthony ; Green, Cameron ; Higgins, Alisa M ; Hullegie, Sebastiaan J ; Kruger, Peter ; Lamontagne, Francois ; Litton, Edward ; Marshall, John ; McGlothlin, Anna ; McGuinness, Shay ; Mouncey, Paul ; Murthy, Srinivas ; Nichol, Alistair ; O'Neill, Genevieve K ; Parke, Rachael ; Parker, Jane ; Rohde, Gernot ; Rowan, Kathryn ; Turner, Anne ; Young, Paul ; Derde, Lennie ; McArthur, Colin ; Webb, Steven A</creator><creatorcontrib>Angus, Derek C ; Berry, Scott ; Lewis, Roger J ; Al-Beidh, Farah ; Arabi, Yaseen ; van Bentum-Puijk, Wilma ; Bhimani, Zahra ; Bonten, Marc ; Broglio, Kristine ; Brunkhorst, Frank ; Cheng, Allen C ; Chiche, Jean-Daniel ; De Jong, Menno ; Detry, Michelle ; Goossens, Herman ; Gordon, Anthony ; Green, Cameron ; Higgins, Alisa M ; Hullegie, Sebastiaan J ; Kruger, Peter ; Lamontagne, Francois ; Litton, Edward ; Marshall, John ; McGlothlin, Anna ; McGuinness, Shay ; Mouncey, Paul ; Murthy, Srinivas ; Nichol, Alistair ; O'Neill, Genevieve K ; Parke, Rachael ; Parker, Jane ; Rohde, Gernot ; Rowan, Kathryn ; Turner, Anne ; Young, Paul ; Derde, Lennie ; McArthur, Colin ; Webb, Steven A</creatorcontrib><description>There is broad interest in improved methods to generate robust evidence regarding best practice, especially in settings where patient conditions are heterogenous and require multiple concomitant therapies. Here, we present the rationale and design of a large, international trial that combines features of adaptive platform trials with pragmatic point-of-care trials to determine best treatment strategies for patients admitted to an intensive care unit with severe community-acquired pneumonia. The trial uses a novel design, entitled "a randomized embedded multifactorial adaptive platform." The design has five key features:
) randomization, allowing robust causal inference;
) embedding of study procedures into routine care processes, facilitating enrollment, trial efficiency, and generalizability;
) a multifactorial statistical model comparing multiple interventions across multiple patient subgroups;
) response-adaptive randomization with preferential assignment to those interventions that appear most favorable; and
) a platform structured to permit continuous, potentially perpetual enrollment beyond the evaluation of the initial treatments. The trial randomizes patients to multiple interventions within four treatment domains: antibiotics, antiviral therapy for influenza, host immunomodulation with extended macrolide therapy, and alternative corticosteroid regimens, representing 240 treatment regimens. The trial generates estimates of superiority, inferiority, and equivalence between regimens on the primary outcome of 90-day mortality, stratified by presence or absence of concomitant shock and proven or suspected influenza infection. The trial will also compare ventilatory and oxygenation strategies, and has capacity to address additional questions rapidly during pandemic respiratory infections. As of January 2020, REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) was approved and enrolling patients in 52 intensive care units in 13 countries on 3 continents. In February, it transitioned into pandemic mode with several design adaptations for coronavirus disease 2019. Lessons learned from the design and conduct of this trial should aid in dissemination of similar platform initiatives in other disease areas.Clinical trial registered with www.clinicaltrials.gov (NCT02735707).</description><identifier>ISSN: 2329-6933</identifier><identifier>ISSN: 2325-6621</identifier><identifier>EISSN: 2325-6621</identifier><identifier>DOI: 10.1513/annalsats.202003-192sd</identifier><identifier>PMID: 32267771</identifier><language>eng</language><publisher>United States: American Thoracic Society</publisher><subject>Adaptive Clinical Trials as Topic ; Anti-Bacterial Agents - therapeutic use ; Antiviral Agents - therapeutic use ; Betacoronavirus ; Clinical Study Design ; Clinical trials ; Community-Acquired Infections - therapy ; Coronavirus Infections - therapy ; COVID-19 ; Evidence-Based Medicine ; Humans ; Influenza, Human - therapy ; Intensive care ; Medical treatment ; Pandemics ; Pneumonia ; Pneumonia - therapy ; Pneumonia, Viral - therapy ; Point-of-Care Systems ; Randomized Controlled Trials as Topic ; SARS-CoV-2</subject><ispartof>Annals of the American Thoracic Society, 2020-07, Vol.17 (7), p.879-891</ispartof><rights>Copyright American Thoracic Society Jul 2020</rights><rights>Copyright © 2020 by the American Thoracic Society 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c561t-e88cd873c5ba4c55b98dc823bfe3b0fda80357410245a90b793e13117cb1334b3</citedby><cites>FETCH-LOGICAL-c561t-e88cd873c5ba4c55b98dc823bfe3b0fda80357410245a90b793e13117cb1334b3</cites><orcidid>0000-0002-0360-3427 ; 0000-0003-4891-4031 ; 0000-0002-6433-6254 ; 0000-0002-0419-547X ; 0000-0002-0020-4869 ; 0000-0002-8132-8651 ; 0000-0002-7026-5181 ; 0000-0002-8380-4738 ; 0000-0003-0274-7936 ; 0000-0002-9476-839X ; 0000-0002-7066-2558 ; 0000-0002-2794-1439 ; 0000-0002-9079-6166 ; 0000-0001-8295-7559 ; 0000-0002-3428-3083 ; 0000-0001-9134-9045 ; 0000-0003-0620-4787 ; 0000-0003-0370-0080 ; 0000-0002-3216-2958 ; 0000-0002-4689-1238 ; 0000-0002-3577-5629 ; 0000-0002-7902-6291 ; 0000-0002-4092-1424 ; 0000-0002-5125-6829 ; 0000-0003-3152-116X ; 0000-0003-4209-0334 ; 0000-0001-6060-5966 ; 0000-0003-4701-463X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32267771$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Angus, Derek C</creatorcontrib><creatorcontrib>Berry, Scott</creatorcontrib><creatorcontrib>Lewis, Roger J</creatorcontrib><creatorcontrib>Al-Beidh, Farah</creatorcontrib><creatorcontrib>Arabi, Yaseen</creatorcontrib><creatorcontrib>van Bentum-Puijk, Wilma</creatorcontrib><creatorcontrib>Bhimani, Zahra</creatorcontrib><creatorcontrib>Bonten, Marc</creatorcontrib><creatorcontrib>Broglio, Kristine</creatorcontrib><creatorcontrib>Brunkhorst, Frank</creatorcontrib><creatorcontrib>Cheng, Allen C</creatorcontrib><creatorcontrib>Chiche, Jean-Daniel</creatorcontrib><creatorcontrib>De Jong, Menno</creatorcontrib><creatorcontrib>Detry, Michelle</creatorcontrib><creatorcontrib>Goossens, Herman</creatorcontrib><creatorcontrib>Gordon, Anthony</creatorcontrib><creatorcontrib>Green, Cameron</creatorcontrib><creatorcontrib>Higgins, Alisa M</creatorcontrib><creatorcontrib>Hullegie, Sebastiaan J</creatorcontrib><creatorcontrib>Kruger, Peter</creatorcontrib><creatorcontrib>Lamontagne, Francois</creatorcontrib><creatorcontrib>Litton, Edward</creatorcontrib><creatorcontrib>Marshall, John</creatorcontrib><creatorcontrib>McGlothlin, Anna</creatorcontrib><creatorcontrib>McGuinness, Shay</creatorcontrib><creatorcontrib>Mouncey, Paul</creatorcontrib><creatorcontrib>Murthy, Srinivas</creatorcontrib><creatorcontrib>Nichol, Alistair</creatorcontrib><creatorcontrib>O'Neill, Genevieve K</creatorcontrib><creatorcontrib>Parke, Rachael</creatorcontrib><creatorcontrib>Parker, Jane</creatorcontrib><creatorcontrib>Rohde, Gernot</creatorcontrib><creatorcontrib>Rowan, Kathryn</creatorcontrib><creatorcontrib>Turner, Anne</creatorcontrib><creatorcontrib>Young, Paul</creatorcontrib><creatorcontrib>Derde, Lennie</creatorcontrib><creatorcontrib>McArthur, Colin</creatorcontrib><creatorcontrib>Webb, Steven A</creatorcontrib><title>The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design</title><title>Annals of the American Thoracic Society</title><addtitle>Ann Am Thorac Soc</addtitle><description>There is broad interest in improved methods to generate robust evidence regarding best practice, especially in settings where patient conditions are heterogenous and require multiple concomitant therapies. Here, we present the rationale and design of a large, international trial that combines features of adaptive platform trials with pragmatic point-of-care trials to determine best treatment strategies for patients admitted to an intensive care unit with severe community-acquired pneumonia. The trial uses a novel design, entitled "a randomized embedded multifactorial adaptive platform." The design has five key features:
) randomization, allowing robust causal inference;
) embedding of study procedures into routine care processes, facilitating enrollment, trial efficiency, and generalizability;
) a multifactorial statistical model comparing multiple interventions across multiple patient subgroups;
) response-adaptive randomization with preferential assignment to those interventions that appear most favorable; and
) a platform structured to permit continuous, potentially perpetual enrollment beyond the evaluation of the initial treatments. The trial randomizes patients to multiple interventions within four treatment domains: antibiotics, antiviral therapy for influenza, host immunomodulation with extended macrolide therapy, and alternative corticosteroid regimens, representing 240 treatment regimens. The trial generates estimates of superiority, inferiority, and equivalence between regimens on the primary outcome of 90-day mortality, stratified by presence or absence of concomitant shock and proven or suspected influenza infection. The trial will also compare ventilatory and oxygenation strategies, and has capacity to address additional questions rapidly during pandemic respiratory infections. As of January 2020, REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) was approved and enrolling patients in 52 intensive care units in 13 countries on 3 continents. In February, it transitioned into pandemic mode with several design adaptations for coronavirus disease 2019. Lessons learned from the design and conduct of this trial should aid in dissemination of similar platform initiatives in other disease areas.Clinical trial registered with www.clinicaltrials.gov (NCT02735707).</description><subject>Adaptive Clinical Trials as Topic</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Betacoronavirus</subject><subject>Clinical Study Design</subject><subject>Clinical trials</subject><subject>Community-Acquired Infections - therapy</subject><subject>Coronavirus Infections - therapy</subject><subject>COVID-19</subject><subject>Evidence-Based Medicine</subject><subject>Humans</subject><subject>Influenza, Human - therapy</subject><subject>Intensive care</subject><subject>Medical treatment</subject><subject>Pandemics</subject><subject>Pneumonia</subject><subject>Pneumonia - therapy</subject><subject>Pneumonia, Viral - therapy</subject><subject>Point-of-Care Systems</subject><subject>Randomized Controlled Trials as Topic</subject><subject>SARS-CoV-2</subject><issn>2329-6933</issn><issn>2325-6621</issn><issn>2325-6621</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkUtP3DAUhaOqqCDgLyBL3dBFpn7EsbOpFA3ThwTqaGa6thzbAaPEHmwHabrjn2MYigpe2FfyOefeq68ozhCcIYrIV-mcHKJMcYYhhpCUqMFRfyiOMMG0rGuMPj7XTVk3hBwWpzHewnw4RZw1n4pDgnHNGENHxcPmxoDV4qpdlvN2Cc5X0mk_2r9Gg8XYGa1zcTUNyfZSJR-sHECr5TbZewOWg0y9DyPIF5j7cZycTbtSqrvJhuxbOjON3ln5BazTpHczsJLJ-jy7AbkNuDDRXruT4qDP25jTl_e4-PN9sZn_LC9___g1by9LRWuUSsO50pwRRTtZKUq7hmvFMel6QzrYa8khoaxCEFdUNrBjDTGIIMRUhwipOnJcfNvnbqduNFoZl4IcxDbYUYad8NKKtz_O3ohrfy8YwRzxOgecvwQEfzeZmMRoozLDIJ3xUxSYcA4hghXM0s_vpLd-Ck_QBK5QwyjEhGVVvVep4GMMpn8dBkHxBFq0z6DbzVrsQYsMen2RjWf_r_Jq-4eVPAJ6Raej</recordid><startdate>202007</startdate><enddate>202007</enddate><creator>Angus, Derek C</creator><creator>Berry, Scott</creator><creator>Lewis, Roger J</creator><creator>Al-Beidh, Farah</creator><creator>Arabi, Yaseen</creator><creator>van Bentum-Puijk, Wilma</creator><creator>Bhimani, Zahra</creator><creator>Bonten, Marc</creator><creator>Broglio, Kristine</creator><creator>Brunkhorst, Frank</creator><creator>Cheng, Allen C</creator><creator>Chiche, Jean-Daniel</creator><creator>De Jong, Menno</creator><creator>Detry, Michelle</creator><creator>Goossens, Herman</creator><creator>Gordon, Anthony</creator><creator>Green, Cameron</creator><creator>Higgins, Alisa M</creator><creator>Hullegie, Sebastiaan J</creator><creator>Kruger, Peter</creator><creator>Lamontagne, Francois</creator><creator>Litton, Edward</creator><creator>Marshall, John</creator><creator>McGlothlin, Anna</creator><creator>McGuinness, Shay</creator><creator>Mouncey, Paul</creator><creator>Murthy, Srinivas</creator><creator>Nichol, Alistair</creator><creator>O'Neill, Genevieve K</creator><creator>Parke, Rachael</creator><creator>Parker, Jane</creator><creator>Rohde, Gernot</creator><creator>Rowan, Kathryn</creator><creator>Turner, Anne</creator><creator>Young, Paul</creator><creator>Derde, Lennie</creator><creator>McArthur, Colin</creator><creator>Webb, Steven A</creator><general>American Thoracic Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0360-3427</orcidid><orcidid>https://orcid.org/0000-0003-4891-4031</orcidid><orcidid>https://orcid.org/0000-0002-6433-6254</orcidid><orcidid>https://orcid.org/0000-0002-0419-547X</orcidid><orcidid>https://orcid.org/0000-0002-0020-4869</orcidid><orcidid>https://orcid.org/0000-0002-8132-8651</orcidid><orcidid>https://orcid.org/0000-0002-7026-5181</orcidid><orcidid>https://orcid.org/0000-0002-8380-4738</orcidid><orcidid>https://orcid.org/0000-0003-0274-7936</orcidid><orcidid>https://orcid.org/0000-0002-9476-839X</orcidid><orcidid>https://orcid.org/0000-0002-7066-2558</orcidid><orcidid>https://orcid.org/0000-0002-2794-1439</orcidid><orcidid>https://orcid.org/0000-0002-9079-6166</orcidid><orcidid>https://orcid.org/0000-0001-8295-7559</orcidid><orcidid>https://orcid.org/0000-0002-3428-3083</orcidid><orcidid>https://orcid.org/0000-0001-9134-9045</orcidid><orcidid>https://orcid.org/0000-0003-0620-4787</orcidid><orcidid>https://orcid.org/0000-0003-0370-0080</orcidid><orcidid>https://orcid.org/0000-0002-3216-2958</orcidid><orcidid>https://orcid.org/0000-0002-4689-1238</orcidid><orcidid>https://orcid.org/0000-0002-3577-5629</orcidid><orcidid>https://orcid.org/0000-0002-7902-6291</orcidid><orcidid>https://orcid.org/0000-0002-4092-1424</orcidid><orcidid>https://orcid.org/0000-0002-5125-6829</orcidid><orcidid>https://orcid.org/0000-0003-3152-116X</orcidid><orcidid>https://orcid.org/0000-0003-4209-0334</orcidid><orcidid>https://orcid.org/0000-0001-6060-5966</orcidid><orcidid>https://orcid.org/0000-0003-4701-463X</orcidid></search><sort><creationdate>202007</creationdate><title>The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design</title><author>Angus, Derek C ; Berry, Scott ; Lewis, Roger J ; Al-Beidh, Farah ; Arabi, Yaseen ; van Bentum-Puijk, Wilma ; Bhimani, Zahra ; Bonten, Marc ; Broglio, Kristine ; Brunkhorst, Frank ; Cheng, Allen C ; Chiche, Jean-Daniel ; De Jong, Menno ; Detry, Michelle ; Goossens, Herman ; Gordon, Anthony ; Green, Cameron ; Higgins, Alisa M ; Hullegie, Sebastiaan J ; Kruger, Peter ; Lamontagne, Francois ; Litton, Edward ; Marshall, John ; McGlothlin, Anna ; McGuinness, Shay ; Mouncey, Paul ; Murthy, Srinivas ; Nichol, Alistair ; O'Neill, Genevieve K ; Parke, Rachael ; Parker, Jane ; Rohde, Gernot ; Rowan, Kathryn ; Turner, Anne ; Young, Paul ; Derde, Lennie ; McArthur, Colin ; Webb, Steven A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c561t-e88cd873c5ba4c55b98dc823bfe3b0fda80357410245a90b793e13117cb1334b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adaptive Clinical Trials as Topic</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Betacoronavirus</topic><topic>Clinical Study Design</topic><topic>Clinical trials</topic><topic>Community-Acquired Infections - therapy</topic><topic>Coronavirus Infections - therapy</topic><topic>COVID-19</topic><topic>Evidence-Based Medicine</topic><topic>Humans</topic><topic>Influenza, Human - therapy</topic><topic>Intensive care</topic><topic>Medical treatment</topic><topic>Pandemics</topic><topic>Pneumonia</topic><topic>Pneumonia - therapy</topic><topic>Pneumonia, Viral - therapy</topic><topic>Point-of-Care Systems</topic><topic>Randomized Controlled Trials as Topic</topic><topic>SARS-CoV-2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Angus, Derek C</creatorcontrib><creatorcontrib>Berry, Scott</creatorcontrib><creatorcontrib>Lewis, Roger J</creatorcontrib><creatorcontrib>Al-Beidh, Farah</creatorcontrib><creatorcontrib>Arabi, Yaseen</creatorcontrib><creatorcontrib>van Bentum-Puijk, Wilma</creatorcontrib><creatorcontrib>Bhimani, Zahra</creatorcontrib><creatorcontrib>Bonten, Marc</creatorcontrib><creatorcontrib>Broglio, Kristine</creatorcontrib><creatorcontrib>Brunkhorst, Frank</creatorcontrib><creatorcontrib>Cheng, Allen C</creatorcontrib><creatorcontrib>Chiche, Jean-Daniel</creatorcontrib><creatorcontrib>De Jong, Menno</creatorcontrib><creatorcontrib>Detry, Michelle</creatorcontrib><creatorcontrib>Goossens, Herman</creatorcontrib><creatorcontrib>Gordon, Anthony</creatorcontrib><creatorcontrib>Green, Cameron</creatorcontrib><creatorcontrib>Higgins, Alisa M</creatorcontrib><creatorcontrib>Hullegie, Sebastiaan J</creatorcontrib><creatorcontrib>Kruger, Peter</creatorcontrib><creatorcontrib>Lamontagne, Francois</creatorcontrib><creatorcontrib>Litton, Edward</creatorcontrib><creatorcontrib>Marshall, John</creatorcontrib><creatorcontrib>McGlothlin, Anna</creatorcontrib><creatorcontrib>McGuinness, Shay</creatorcontrib><creatorcontrib>Mouncey, Paul</creatorcontrib><creatorcontrib>Murthy, Srinivas</creatorcontrib><creatorcontrib>Nichol, Alistair</creatorcontrib><creatorcontrib>O'Neill, Genevieve K</creatorcontrib><creatorcontrib>Parke, Rachael</creatorcontrib><creatorcontrib>Parker, Jane</creatorcontrib><creatorcontrib>Rohde, Gernot</creatorcontrib><creatorcontrib>Rowan, Kathryn</creatorcontrib><creatorcontrib>Turner, Anne</creatorcontrib><creatorcontrib>Young, Paul</creatorcontrib><creatorcontrib>Derde, Lennie</creatorcontrib><creatorcontrib>McArthur, Colin</creatorcontrib><creatorcontrib>Webb, Steven A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of the American Thoracic Society</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Angus, Derek C</au><au>Berry, Scott</au><au>Lewis, Roger J</au><au>Al-Beidh, Farah</au><au>Arabi, Yaseen</au><au>van Bentum-Puijk, Wilma</au><au>Bhimani, Zahra</au><au>Bonten, Marc</au><au>Broglio, Kristine</au><au>Brunkhorst, Frank</au><au>Cheng, Allen C</au><au>Chiche, Jean-Daniel</au><au>De Jong, Menno</au><au>Detry, Michelle</au><au>Goossens, Herman</au><au>Gordon, Anthony</au><au>Green, Cameron</au><au>Higgins, Alisa M</au><au>Hullegie, Sebastiaan J</au><au>Kruger, Peter</au><au>Lamontagne, Francois</au><au>Litton, Edward</au><au>Marshall, John</au><au>McGlothlin, Anna</au><au>McGuinness, Shay</au><au>Mouncey, Paul</au><au>Murthy, Srinivas</au><au>Nichol, Alistair</au><au>O'Neill, Genevieve K</au><au>Parke, Rachael</au><au>Parker, Jane</au><au>Rohde, Gernot</au><au>Rowan, Kathryn</au><au>Turner, Anne</au><au>Young, Paul</au><au>Derde, Lennie</au><au>McArthur, Colin</au><au>Webb, Steven A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design</atitle><jtitle>Annals of the American Thoracic Society</jtitle><addtitle>Ann Am Thorac Soc</addtitle><date>2020-07</date><risdate>2020</risdate><volume>17</volume><issue>7</issue><spage>879</spage><epage>891</epage><pages>879-891</pages><issn>2329-6933</issn><issn>2325-6621</issn><eissn>2325-6621</eissn><abstract>There is broad interest in improved methods to generate robust evidence regarding best practice, especially in settings where patient conditions are heterogenous and require multiple concomitant therapies. Here, we present the rationale and design of a large, international trial that combines features of adaptive platform trials with pragmatic point-of-care trials to determine best treatment strategies for patients admitted to an intensive care unit with severe community-acquired pneumonia. The trial uses a novel design, entitled "a randomized embedded multifactorial adaptive platform." The design has five key features:
) randomization, allowing robust causal inference;
) embedding of study procedures into routine care processes, facilitating enrollment, trial efficiency, and generalizability;
) a multifactorial statistical model comparing multiple interventions across multiple patient subgroups;
) response-adaptive randomization with preferential assignment to those interventions that appear most favorable; and
) a platform structured to permit continuous, potentially perpetual enrollment beyond the evaluation of the initial treatments. The trial randomizes patients to multiple interventions within four treatment domains: antibiotics, antiviral therapy for influenza, host immunomodulation with extended macrolide therapy, and alternative corticosteroid regimens, representing 240 treatment regimens. The trial generates estimates of superiority, inferiority, and equivalence between regimens on the primary outcome of 90-day mortality, stratified by presence or absence of concomitant shock and proven or suspected influenza infection. The trial will also compare ventilatory and oxygenation strategies, and has capacity to address additional questions rapidly during pandemic respiratory infections. As of January 2020, REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) was approved and enrolling patients in 52 intensive care units in 13 countries on 3 continents. In February, it transitioned into pandemic mode with several design adaptations for coronavirus disease 2019. Lessons learned from the design and conduct of this trial should aid in dissemination of similar platform initiatives in other disease areas.Clinical trial registered with www.clinicaltrials.gov (NCT02735707).</abstract><cop>United States</cop><pub>American Thoracic Society</pub><pmid>32267771</pmid><doi>10.1513/annalsats.202003-192sd</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-0360-3427</orcidid><orcidid>https://orcid.org/0000-0003-4891-4031</orcidid><orcidid>https://orcid.org/0000-0002-6433-6254</orcidid><orcidid>https://orcid.org/0000-0002-0419-547X</orcidid><orcidid>https://orcid.org/0000-0002-0020-4869</orcidid><orcidid>https://orcid.org/0000-0002-8132-8651</orcidid><orcidid>https://orcid.org/0000-0002-7026-5181</orcidid><orcidid>https://orcid.org/0000-0002-8380-4738</orcidid><orcidid>https://orcid.org/0000-0003-0274-7936</orcidid><orcidid>https://orcid.org/0000-0002-9476-839X</orcidid><orcidid>https://orcid.org/0000-0002-7066-2558</orcidid><orcidid>https://orcid.org/0000-0002-2794-1439</orcidid><orcidid>https://orcid.org/0000-0002-9079-6166</orcidid><orcidid>https://orcid.org/0000-0001-8295-7559</orcidid><orcidid>https://orcid.org/0000-0002-3428-3083</orcidid><orcidid>https://orcid.org/0000-0001-9134-9045</orcidid><orcidid>https://orcid.org/0000-0003-0620-4787</orcidid><orcidid>https://orcid.org/0000-0003-0370-0080</orcidid><orcidid>https://orcid.org/0000-0002-3216-2958</orcidid><orcidid>https://orcid.org/0000-0002-4689-1238</orcidid><orcidid>https://orcid.org/0000-0002-3577-5629</orcidid><orcidid>https://orcid.org/0000-0002-7902-6291</orcidid><orcidid>https://orcid.org/0000-0002-4092-1424</orcidid><orcidid>https://orcid.org/0000-0002-5125-6829</orcidid><orcidid>https://orcid.org/0000-0003-3152-116X</orcidid><orcidid>https://orcid.org/0000-0003-4209-0334</orcidid><orcidid>https://orcid.org/0000-0001-6060-5966</orcidid><orcidid>https://orcid.org/0000-0003-4701-463X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2329-6933 |
ispartof | Annals of the American Thoracic Society, 2020-07, Vol.17 (7), p.879-891 |
issn | 2329-6933 2325-6621 2325-6621 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7328186 |
source | MEDLINE; American Thoracic Society (ATS) Journals Online; Alma/SFX Local Collection |
subjects | Adaptive Clinical Trials as Topic Anti-Bacterial Agents - therapeutic use Antiviral Agents - therapeutic use Betacoronavirus Clinical Study Design Clinical trials Community-Acquired Infections - therapy Coronavirus Infections - therapy COVID-19 Evidence-Based Medicine Humans Influenza, Human - therapy Intensive care Medical treatment Pandemics Pneumonia Pneumonia - therapy Pneumonia, Viral - therapy Point-of-Care Systems Randomized Controlled Trials as Topic SARS-CoV-2 |
title | The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T08%3A26%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20REMAP-CAP%20(Randomized%20Embedded%20Multifactorial%20Adaptive%20Platform%20for%20Community-acquired%20Pneumonia)%20Study.%20Rationale%20and%20Design&rft.jtitle=Annals%20of%20the%20American%20Thoracic%20Society&rft.au=Angus,%20Derek%20C&rft.date=2020-07&rft.volume=17&rft.issue=7&rft.spage=879&rft.epage=891&rft.pages=879-891&rft.issn=2329-6933&rft.eissn=2325-6621&rft_id=info:doi/10.1513/annalsats.202003-192sd&rft_dat=%3Cproquest_pubme%3E2419750237%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2419750237&rft_id=info:pmid/32267771&rfr_iscdi=true |